Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1

Conditions

Primary Myelofibrosis 1Polycythemia Vera 1Mesothelioma, Malignant 1Carcinoma, Non-Small-Cell Lung 1Camurati-Engelmann Syndrome 1Breast Neoplasms 1Brain Neoplasms 1

Interventions

Cisplatin 28Pemetrexed 24pembrolizumab 12Nivolumab 10Carboplatin 9atezolizumab 7Gemcitabine 7Cyclophosphamide 7durvalumab 6Drug Therapy 6sodium thiosulfate 5Radiotherapy, Intensity-Modulated 5tremelimumab 4aldesleukin 4Radiotherapy 4Interleukin-2 4sargramostim 3Vinorelbine 3Platinum 3Photochemotherapy 3Ipilimumab 3Doxorubicin 3Dihematoporphyrin Ether 3Chemotherapy, Adjuvant 3Cerebral Decortication 3vatalanib 2regorafenib 2niraparib 2lenvatinib 2cemiplimab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Mesothelioma, Malignant × fresolimumab × Clear all
NCT01112293 2020-04-10

Anti-TGF Monoclonal Antibody (GC1008) in Relapsed Malignant Pleural Mesothelioma

Abramson Cancer Center at Penn Medicine

Phase 2 Completed
14 enrolled 10 charts
Other solid neoplasmThoracic

Mesothelioma, Malignant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡